{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:16Z","timestamp":1759451956590,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T18:00:40Z","timestamp":1579716040000},"page":"1962-1967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants"],"prefix":"10.1016","volume":"38","author":[{"given":"Eddy","family":"Fadlyana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-0708","authenticated-orcid":false,"given":"Meita","family":"Dhamayanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodman","family":"Tarigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rini","family":"Mulia Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novilia","family":"Sjafri Bachtiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy B.","family":"Kartasasmita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusnandi","family":"Rusmil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.007_b0005","unstructured":"(WHO) WHO. Vaccine-associated paralytic polio (VAPP) and vaccine-derived poliovirus (VDPV) Vaccine derived poliovirus (VDPV); 2015."},{"key":"10.1016\/j.vaccine.2020.01.007_b0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.007_b0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.007_b0020","unstructured":"Global Polio Eradication Initiative. This Week \u2013 GPEI n.d. http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/ [accessed December 19, 2019]."},{"key":"10.1016\/j.vaccine.2020.01.007_b0025","unstructured":"Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013:1\u201389."},{"key":"10.1016\/j.vaccine.2020.01.007_b0030","unstructured":"(WHO) WHO. Background and Technical Rationale for Introduction of One dose of Inactivated Polio Vaccine (IPV) in Routine Immunization Schedule A handbook for training regional consultants and briefing NITAG members on technical aspects related to introduction of IPV. 2014."},{"key":"10.1016\/j.vaccine.2020.01.007_b0035","doi-asserted-by":"crossref","unstructured":"(WHO) WHO. Polio vaccines: WHO position paper, January 2014 \u2013 Recommendations. Vaccine 2014;32(33):4117-4118. 10.1016\/j.vaccine.2014.04.023.","DOI":"10.1016\/j.vaccine.2014.04.023"},{"key":"10.1016\/j.vaccine.2020.01.007_b0040","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-015-0525-2","article-title":"The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule","author":"Rusmil","year":"2015","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.vaccine.2020.01.007_b0045","first-page":"29","article-title":"WMA declaration of Helsinki-Ethical principles","author":"Kong","year":"2013","journal-title":"World Med Assoc"},{"key":"10.1016\/j.vaccine.2020.01.007_b0050","unstructured":"ICH GCP. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) 2016. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf [accessed December 15, 2018]."},{"key":"10.1016\/j.vaccine.2020.01.007_b0055","unstructured":"Expert Committee on Biological Standardization. Guidelines on clinical evaluation of vaccines: regulatory expectations Revision of WHO TRS 924, Annex 1 2016:1\u201392."},{"key":"10.1016\/j.vaccine.2020.01.007_b0060","unstructured":"WHO | OPV (Oral Polio Vaccine) bivalent Types 1 and 3 (20 dose vial). WHO 2016. <https:\/\/www.who.int\/immunization_standards\/vaccine_quality\/PQ_196_bOPV13_20_dose_Vial_Biofarma\/en\/> [accessed December 15, 2018]."},{"key":"10.1016\/j.vaccine.2020.01.007_b0065","unstructured":"PT Bio Farma. Pentabio Vaccine (DTP-HB-Hib) PT BIO FARMA (PERSERO); 2018."},{"key":"10.1016\/j.vaccine.2020.01.007_b0070","unstructured":"(WHO) WHO. Polio Vaccine \u2013 Inactivated (IPV) ShanIPV 2018. <https:\/\/extranet.who.int\/gavi\/PQ_Web\/PreviewVaccine.aspx?nav=0&ID=333> [accessed December 15, 2018]."},{"key":"10.1016\/j.vaccine.2020.01.007_b0075","unstructured":"(WHO) WHO. Guidelines for WHO\/EPI Collaborative Studies on Poliomyelitis. Standard Procedure for Determining Immunity to Poliovirus Using the Microneutralization Test. WHO\/EPI\/GEN\/93.9 n.d."},{"key":"10.1016\/j.vaccine.2020.01.007_b0080","unstructured":"Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). World Heal Organ \u2013 Tech Rep Ser 2014."},{"key":"10.1016\/j.vaccine.2020.01.007_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu060","article-title":"Switch from oral to inactivated poliovirus vaccine in Yogyakarta province, Indonesia: summary of coverage, immunity, and environmental surveillance","author":"Wahjuhono","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.007_b0090","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.01.007_b0095","unstructured":"Tanuwidjaja, Suganda; Rusmil, Kusnandi; Fadlyana E et al. Comparative Evaluation of Immunogenicity & Safety of mOPV1 (Bio Farma) with tOPV (Bio Farma) in Indonesian Children, Final Report. Bandung; 2008."},{"key":"10.1016\/j.vaccine.2020.01.007_b0100","unstructured":"Rusmil, Kusnandi; Fadlyana, Eddy et al. The antibody response and safety after National Immunization Day with type 1 monovalent Oral Polio Vaccine (mOPV1 Bio Farma) in Bandung, Final Report. Bandung; 2006."},{"key":"10.1016\/j.vaccine.2020.01.007_b0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/jix577","article-title":"Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan","volume":"217","author":"Saleem","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.007_b0110","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.007_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00156819","article-title":"Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule","volume":"5","author":"Swartz","year":"1989","journal-title":"Eur J Epidemiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:21Z","timestamp":1759401501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20300116"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}